Early into the coronavirus disease 2019 (COVID-19) pandemic, some small, inconclusive studies hinted that patients receiving anticancer treatments may be at increased risk of mortality from COVID-19; however, COVID-19-related mortality in patients with cancer may be driven by age, gender, and other comorbidities, not recent anticancer treatment, according to results from a large prospective cohort study published in The Lancet.

The study was a product of the UK Coronavirus Cancer Monitoring Project (UKCCMP). The investigators aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in a large cohort of patients with cancer who were receiving cytotoxic chemotherapy and other anticancer treatments.

All patients with active cancer and presenting to a network of cancer centers in the UK with confirmed COVID-19 (positive viral real-time polymerase chair reaction assay) were eligible for UKCCMP enrollment. Local reporting site personnel were encouraged to enter data on a real-time basis. The primary endpoint was all-cause mortality or discharge from the hospital. Outcomes were monitored from March 18 until April 26, 2020.


Continue Reading

The investigators assessed data from 800 patients with cancer and symptomatic COVID-19. COVID-19 disease course was mild for 412 (52%) patients, severe for 187 (23%) patients, and critical for 173 (22%) patients. In total, 226 (28%) patients died.

The risk of death was significantly associated with advanced age (odds ratio [OR], 9.42; P <.0001), male gender (OR, 1.67; P =.003; patient deaths, 33% of all men vs 20% of all women), and having other comorbidities, specifically hypertension (OR, 1.95; P <.001; 41% of those who died vs 27% of survivors; P <.001) and cardiovascular disease (OR, 2.32; 21% of those who died vs 11% of survivors; P <.001).

Overall, 281 of the 800 (35%) patients had received cytotoxic chemotherapy within 4 weeks of testing positive for COVID-19. Those who had recently received chemotherapy treatment had a similar mortality rate compared with those who had not (27% vs 29%, respectively).

In a multivariate analysis adjusting for age, gender, and comorbidities, no significant difference in mortality from COVID-19 disease was found between patients who had received recent chemotherapy treatment compared with those who had not (OR, 1.18; P =.380). Patients who had received immunotherapy, hormonal therapy, targeted therapy, or radiotherapy within the past 4 weeks also had no additional risk of death.

“Our data are strongly indicative that COVID-19 mortality in patients with cancer is principally driven by advancing age and the presence of other non-cancer comorbidities,” wrote the authors. “At a population level, our data do not suggest that chemotherapy or anticancer treatments will necessarily increase the risk of mortality from COVID-19, and gives confidence to oncologists and other clinicians that delivery of effective anticancer regimens should continue during this difficult time.”

Reference

Lee LYW, Cazier JB, Starkey T, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study [published online May 28, 2020]. Lancet. doi: 10.1016/S0140-6736(20)31173-9

This article originally appeared on Hematology Advisor